Caffeine, cyp1a2 genotype, and risk of myocardial infarction
DOI:
https://doi.org/10.55312/op.vi2.4369Abstract
Myocardial infarction is one of the life-threatening pathologies. The aim of this study is the recognition of the link between coff ee consumption and tobacco smoke with cardiovascular diseases. Methods: The study was conducted by collecting information from open network pharmacies in Shkoder, in QSUT “Mother Teresa” and in Durrës. For each patient was collected data on age, occupation, use of coff ee, energetic drinks, physical activity and family history. The data is processed statistically. There is also taken sample - case - control to determine experimentally the relationship between consumption of coff ee and the CYP1A2 genotypes with the risk for IM. Results, Conclusions: The incidence for HT illness and the risk for MI increase with the use of coff ee, cigarettes on persons who are homozygote for the variant 1F of caff eine.Keywords:
Genotype, CYP1A2, 1F, Myocardial Infarction, Metabolism.Downloads
References
-
Cammack, R., Oxford Dictionary of Biochemistry and Molecular Biology - Revised Edition. Oxford University Press; 2006; 493–498.
-
Kot, M. & Daniel, W.A., Caff eine as a marker substrate for testing cytochrome P450 activityin human and rat.Pharmacol Rep.2008; 60(6):789-797.
-
R. Viani, “The composition of coff ee”, in Caff eine, Coff ee and Health, S. Garatini, Ed. Raven Press, New York, NY, USA ; 1993; 17–41.
-
L. Missiaen, J. B. Parys, H. De Smedt, B. Himpens, and R. Casteels,“Inhibition of inositol trisphosphate-induced calcium release
-
by caff eine is prevented by ATP”, Biochemical Journal, 1994; 300:1; 81–84.
-
C. Martin, C. Dacquet, C. Mironneau, and J. Mirroneau, “Caff eine-induced inhibition of calcium channel current in cultured smooth muscle cells from pregnant rat myometrium”, British Journal of Pharmacology, 1989; 98; 2; 493–498.
-
V. Ralevic and G. Burnstock. “Receptors for purines and pyrimidines”, Pharmacological Reviews; 1998; 50: 3; 413–492.
-
Kathrin Klein, Stefan Einter, MiiaTurpeinen, Matthias Scheab, Ulrich M. Zanger, Patheay- Targeted Pharmacogenomics of CYP1A2 in
-
Human Liver. 2010; 493–498.
-
Gunes, A., Dahl, M., Variation in CYP1A2 activity and its clinical implications: infl uence of environmental factors and genetic polymorphisms.2008; 625–637.
-
Marilyn, C., Cornelis., Ahmed El-Sohemy., Edmond K. Kabagambe., Hannia Campos, Coff ee, CYP1A2 Genotype, and Risk of, Myocardial Infarction.2006; 1135-1141.
-
Cornelis, M. C., El-Sohemy, A., Campos, H., Genetic polymorphism of CYP1A2 increases the risk ofmyocardial infarction. 2004; 41:758–762.
-
Caff eine-and-Activation-Theory-Eff ects-on-Health-and-Behavior-Smith; 2007; 493–498
References
Cammack, R., Oxford Dictionary of Biochemistry and Molecular Biology - Revised Edition. Oxford University Press; 2006; 493–498.
Kot, M. & Daniel, W.A., Caff eine as a marker substrate for testing cytochrome P450 activityin human and rat.Pharmacol Rep.2008; 60(6):789-797.
R. Viani, “The composition of coff ee”, in Caff eine, Coff ee and Health, S. Garatini, Ed. Raven Press, New York, NY, USA ; 1993; 17–41.
L. Missiaen, J. B. Parys, H. De Smedt, B. Himpens, and R. Casteels,“Inhibition of inositol trisphosphate-induced calcium release
by caff eine is prevented by ATP”, Biochemical Journal, 1994; 300:1; 81–84.
C. Martin, C. Dacquet, C. Mironneau, and J. Mirroneau, “Caff eine-induced inhibition of calcium channel current in cultured smooth muscle cells from pregnant rat myometrium”, British Journal of Pharmacology, 1989; 98; 2; 493–498.
V. Ralevic and G. Burnstock. “Receptors for purines and pyrimidines”, Pharmacological Reviews; 1998; 50: 3; 413–492.
Kathrin Klein, Stefan Einter, MiiaTurpeinen, Matthias Scheab, Ulrich M. Zanger, Patheay- Targeted Pharmacogenomics of CYP1A2 in
Human Liver. 2010; 493–498.
Gunes, A., Dahl, M., Variation in CYP1A2 activity and its clinical implications: infl uence of environmental factors and genetic polymorphisms.2008; 625–637.
Marilyn, C., Cornelis., Ahmed El-Sohemy., Edmond K. Kabagambe., Hannia Campos, Coff ee, CYP1A2 Genotype, and Risk of, Myocardial Infarction.2006; 1135-1141.
Cornelis, M. C., El-Sohemy, A., Campos, H., Genetic polymorphism of CYP1A2 increases the risk ofmyocardial infarction. 2004; 41:758–762.
Caff eine-and-Activation-Theory-Eff ects-on-Health-and-Behavior-Smith; 2007; 493–498
Shqip
English
Italiano
